A 2004 double-blind, placebo-controlled trial involving 114 patients with AP in combination with a C-reactive protein level exceeding 150 mg/L and/or a CT-verified necrosis, found no significant difference in the incidence of infected pancreatic necrosis between the placebo group and those treated with ciprofloxacin (2 × 400 mg/day) and metronidazole (2 × 500 mg/day) [79]. The gene discussed is CRP; the disease is alkaline phosphatase measurement.